Orbital Therapeutics, a well-funded biotech born out of buzzy base editing company Beam Therapeutics, has shuttered its South San Francisco office.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the successful closing of $270 million Series A financing. The Series A raise was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors.
Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced its initial funding and the entry into a license and research collaboration with Beam Therapeutics. Under the license and collaboration agreement, Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology. Orbital’s exclusive field of use consists of vaccines and certain therapeutic proteins, while Beam’s exclusive field of use consists of gene editing and conditioning for use in cell transplantation.